RCSB PDB - 5G01: An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C (original) (raw)
An Unusual Natural Product Primary Sulfonamide: Synthesis, Carbonic Anhydrase Inhibition and Protein X-Ray Structures of Psammaplin C.
[Mujumdar, P.](/search?q=citation.rcsb%5Fauthors:Mujumdar, P.), [Teruya, K.](/search?q=citation.rcsb%5Fauthors:Teruya, K.), [Tonissen, K.F.](/search?q=citation.rcsb%5Fauthors:Tonissen, K.F.), [Vullo, D.](/search?q=citation.rcsb%5Fauthors:Vullo, D.), [Supuran, C.T.](/search?q=citation.rcsb%5Fauthors:Supuran, C.T.), [Peat, T.S.](/search?q=citation.rcsb%5Fauthors:Peat, T.S.), [Poulsen, S.](/search?q=citation.rcsb%5Fauthors:Poulsen, S.)
(2016) J Med Chem 59: 5462
PubMed: 27172398 Search on PubMed
PubMed Abstract:
Psammaplin C is one of only two described natural product primary sulfonamides. Here we report the synthesis of psammaplin C and evaluate the inhibition profile against therapeutically relevant carbonic anhydrase (CA) zinc metalloenzymes. The compound exhibited unprecedented inhibition of an important cancer-associated isozyme, hCA XII, with a Ki of 0.79 nM. The compound also displayed good isoform selectivity for hCA XII over other CAs. We present the first reported protein X-ray crystal structures of psammaplin C in complex with human CAs. We engineered the easily crystallized hCA II enzyme to mimic both the hCA IX and hCA XII binding sites and then utilized protein X-ray crystallography to determine the binding pose of psammaplin C within the hCA II, hCA IX, and hCA XII mimic active sites, all to high resolution. This is the first time a natural product primary sulfonamide inhibitor has been assessed for inhibition and binding to CAs.
Organizational Affiliation:
Eskitis Institute for Drug Discovery, Griffith University , Don Young Road, Nathan, Queensland 4111, Australia.